Form 4: Heron Therapeutics Executive Exercises Stock Options
SEC Form 4
William P. Forbes, EVP and Chief Development Officer of Heron Therapeutics, reports a transaction involving the exercise of stock options.
Summary
- On April 19, 2025, William P. Forbes, the EVP and Chief Development Officer of Heron Therapeutics, exercised stock options.
- This transaction involved the acquisition of 3,875 shares of common stock.
- Following the transaction, Forbes directly owns 110,872 shares of common stock.
- Forbes also exercised 3,875 Restricted Stock Units.
- Following the transaction, Forbes directly owns 42,617 Restricted Stock Units.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a routine disclosure of stock option exercise.
Positives
- The exercise of stock options by an executive can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard SEC filing related to insider transactions. It is common for executives to receive and exercise stock options as part of their compensation.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the increase in the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 01/19/2024 | Date of grant for restricted stock units, which vest in 16 equal quarterly installments beginning one quarter after this date. |
| 04/19/2025 | Date of transaction: William P. Forbes exercised stock options and Restricted Stock Units. |
| 04/22/2025 | Date of signature on the Form 4 filing. |
Keywords
Heron Therapeutics, HRTX, William P. Forbes, stock options, EVP, Chief Development Officer, Form 4, securities, common stock, restricted stock units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.